PYXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PYXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pyxis Oncology's change in receivables for the quarter that ended in Mar. 2024 was $-8.00 Mil. It means Pyxis Oncology's Accounts Receivable increased by $8.00 Mil from Dec. 2023 to Mar. 2024 .
Pyxis Oncology's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Pyxis Oncology's Accounts Receivable for the quarter that ended in Mar. 2024 was $8.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Pyxis Oncology's Days Sales Outstanding for the three months ended in Mar. 2024 was 45.21.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pyxis Oncology's liquidation value for the three months ended in Mar. 2024 was $126.96 Mil.
The historical data trend for Pyxis Oncology's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Change In Receivables | - | - | - | - | - |
Pyxis Oncology Quarterly Data | |||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | -8.00 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (NAS:PYXS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Pyxis Oncology's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 8 | / | 16.146 | * | 91 |
= | 45.21 |
2. In Ben Graham's calculation of liquidation value, Pyxis Oncology's accounts receivable are only considered to be worth 75% of book value:
Pyxis Oncology's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 157.027 | - | 36.064 | + | 0.75 * 8 | + | 0.5 * 0 |
= | 126.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pyxis Oncology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Pamela Ann Connealy | officer: Chief Financial Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Jitendra Wadhane | officer: Chief Accounting Officer | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Lara Sullivan | director, officer: Chief Executive Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
Jakob Dupont | director | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Pfizer Inc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Pfizer Ventures (us) Llc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Rachel Humphrey | director | C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
Mark Chin | other: Former Director | 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ |
Darren S Cline | director | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Thomas Civik | director | C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bayer World Investments B.v. | 10 percent owner | ENERGIEWEG 1, MIJDRECHT P7 3641 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Ronald Herbst | officer: Chief Scientific Officer | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
From GuruFocus
By sperokesalga sperokesalga • 03-22-2023
By sperokesalga sperokesalga • 05-24-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By GlobeNewswire GlobeNewswire • 12-23-2022
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 08-01-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By sperokesalga sperokesalga • 02-13-2023
By sperokesalga sperokesalga • 05-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.